araag2/HINT huggingface dataset:
Clinical trial NCT00722124 (phase 2/phase 3, status: completed)
Conditions: tobacco dependence
ICD codes: F17.220, F17.221, F17.223, F17.290, F17.291, F17.293, Z81.2
Drugs: s-adenosyl-l-methionine, s-adenosyl-l-methionine
SMILES: [H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O, [H][C@](N)(CC[S+](C)C[C@@]1([H])O[C@@]([H])(N2C=NC3=C(N)N=CN=C23)[C@]([H])(O)[C@]1([H])O)C([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Is at least 18 years of age;

          -  Has smoked more than 10 cigarettes/day for ≥6 months;

          -  Is willing to make a quit attempt;

          -  Is able to participate fully in all aspects of the study;

          -  Has been provided with, understand, and have signed the informed consent.

          -  Is in good health as determined by the physician investigator.

        Exclusion Criteria:

          -  Is clinically significant levels of current depression as assessed by CESD (Score >16)
             and determined by the physician; or have a life-time diagnosis of bipolar disorder,
             schizophrenia or dementia as determined by physician investigator;

          -  Has an unstable medical condition.

          -  Is using other tobacco product and the primary use is NOT cigarettes.

          -  Is currently (within the past 30-days) using antipsychotics or antidepressants;

          -  Is currently (within the past 30-days) using any treatments for tobacco dependence
             (i.e., behavioral therapy, nicotine replacement therapy, bupropion SR, clonidine, or
             nortriptyline);

          -  Is currently using another investigational drug at the time of study enrollment;

          -  Is currently (within the past 30 days) using an herbal product or dietary supplement
             for tobacco abstinence;

          -  Has recent history (in the past 3-months) of alcohol abuse or dependence as assessed
             by the CAGE questionnaire and study investigators;

          -  Has a recent history of drug abuse as assessed by physician interview;

          -  Is pregnant, lactating, or of child bearing potential, likely to become pregnant
             during the medication phase and not willing to use a reliable form of contraception.
             Reliable forms of contraception include diaphragm or condom (with spermicidal),
             injections, intrauterine device [IUD], surgical sterilization and abstinence;

          -  Is a history of any major cardiovascular events in the past 3-months including
             unstable angina, acute MI or coronary angioplasty;

          -  Has clinically significant acute or chronic progressive or unstable neurologic,
             hepatic, renal, cardiovascular, respiratory or metabolic disease;

          -  Is currently on medications interacting with SAMe, including but not limited to,
             antidepressants, MAO inhibitors, levodopa, meperidine, dextromethorphan, pentazocine
             and tramadol;

          -  Has another household member or relative participating in the study;

          -  Has known allergy to SAMe.
Clinical trial NCT00485303 (phase 2, status: completed)
Conditions: prostatic neoplasms, prostate cancer
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: abiraterone acetate, prednisone
SMILES: [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma (malignant epithelial tumor
             with a glandular organization)of the prostate (a gland in the male reproductive system
             found below the bladder and in front of the rectum), but not with neuroendocrine
             (specialized neurons that produce hormones, such as neuropeptides or biogenic amines)
             differentiation or of small cell histology

          -  Prior chemotherapy (treatment of disease, usually cancer, by chemical agents) for
             prostate cancer with regimen(s) containing docetaxel

          -  Documented prostate specific antigen (PSA) progression according to Prostate Specific
             Antigen Working Group (PSAWG) eligibility criteria with a PSA more than (>) 5 nanogram
             per milliliter (ng/mL) or objective progression by Response Evaluation Criteria in
             Solid Tumors (RESIST) criteria

          -  Ongoing androgen deprivation with serum testosterone less than (<) 50 nanogram per
             deciliter (ng/dL)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of less than equal to
             (<=) 2 (Karnofsky Performance Status >= 50 percent)

        Exclusion Criteria:

          -  Active or uncontrolled autoimmune disease (disorder in which a person's immune system
             attacks parts of his or her own body) that may require corticosteroid therapy

          -  Serious or uncontrolled co-existent non-malignant disease, including active and
             uncontrolled infection

          -  Uncontrolled hypertension (high blood pressure)

          -  Hemoglobin <=9.0 gram per deciliter (g/dL) without growth factor or transfusion
             support

          -  Abnormal liver (large organ that helps in many body functions, including digestion,
             metabolism, and storage of substances) function
Clinical trial NCT01476813 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: glycopyrrolate, glycopyrrolate, glycopyrrolate, comparator
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  COPD over 40 years of age (30 to 60% post-bronchodilator FEV1 predictive value)

          -  Patients under Double

          -  Patients under triple therapy (for 1 Mo prior Screening)

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients experiencing a COPD exacerbation requiring use of systemic steroids and/or
             antibiotics, hospitalization

          -  concommitant diseases impacting feasibility or safety
Clinical trial NCT01196234 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: paclitaxel/carboplatin/gefitinib, paclitaxel/carboplatin
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1, [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  More than 18 years of age

          -  Histologically documented non-small cell lung cancer with metastasis (Stage IV) or
             locally advanced (Stage IIIB) with malignant effusion.

          -  At least 1 measurable lesion as defined by RECIST1.0. All target lesions must have a
             unidirectional diameter of at least 1cm. Baseline measurements must be compared within
             4 weeks prior to enrollment.

          -  ECOG PS 0-2

          -  At least 1 week since the last radiotherapy. Patients must have recovered from all
             acute toxicities from radiotherapy.

          -  Patients must have adequate hematologic, renal and liver function as defined by Hb >
             9g/dL, neutrophils > 1000/mm3, platelets > 50,000/mm3, creatinine < 2mg/dL, and AST
             (SGOT) and/or ALT (SGPT) < 5 x UNL (upper normal limit).

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests and other study procedures.

          -  Written and voluntary informed consent understood, signed and dated.

        Exclusion Criteria:

          -  Patients with tumor harboring EGFR mutation.

          -  Prior systemic therapy for NSCLC

          -  Non-smoking patients with adenocarcinoma. But if those patients show wild type EGFR,
             they are eligible to this study.

          -  Symptomatic brain metastasis. Brain metastases stable < 2 weeks before dosing or
             requiring concurrent steroid treatment or with clinical symptoms.

          -  Major surgery within 3 weeks prior to study enrollment.

          -  Previous (less than 3 years ago) or current malignancies at sites other than
             curatively treated in situ carcinoma of cervix, or basal or squamous cell carcinoma of
             the skin.

          -  Severe medical illness or active infection that would impair the ability to receive
             gefitinib.

          -  Pregnancy or breast feeding.
Clinical trial NCT00805012 (phase 2, status: terminated)
Conditions: head and neck squamous cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: docetaxel+cddp, docetaxel+s-1
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Reason stopped: 
    slow accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  histologically confirmed HNSCC

          -  adequate primary site: oral cavity, oropharynx, hypopharynx, nasal cavity, paranasal
             sinus, other head and neck site (except nasopharynx)

          -  at least one measurable lesion

          -  no previous palliative chemotherapy (adjuvant/neoadjuvant chemotherapy and/or
             radiotherapy longer than 6 months ago is permitted)

          -  18 years or older

          -  ECOG 0 or 1

          -  adequate laboratory result

          -  written, informed consent

        Exclusion Criteria:

          -  pregnant or lactating women (negative pregnancy test within 7 days is required for
             women with potential of child-bearing)

          -  experimental drug clinical trial within 30 days

          -  other malignancy (exemption: treated basal cell carcinoma of skin, CIS, cured cancer
             with disease-free interval with more than 5 years)

          -  patient with organ transplantation

          -  grade 2 or more peripheral neuropathy

          -  grade 2 or more hearing loss

          -  severe, medical condition
Clinical trial NCT00046761 (phase 2/phase 3, status: terminated)
Conditions: cerebrovascular accident
ICD codes: A52.05, I67.81, I67.89, I67.9, I67.841, I67.858, I67.848
Drugs: ono-2506
SMILES: CCCCCC[C@@H](CCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must have a clinical diagnosis of acute cortical ischemic stroke.

          -  Patient must be randomized into the study within six hours after the initial onset of
             stroke symptoms.

          -  Patient must have a measurable focal neurological deficit for a minimum duration of 60
             minutes.

          -  Patient must have a CT or MRI examination compatible with the clinical diagnosis of
             acute ischemic stroke.

          -  Patient must have had a pre-stroke mRS scale score of 0 or 1.

          -  Other inclusion criteria as specified in the study protocol.

        Exclusion Criteria:

          -  Patient must not have a body weight of more than 125 kg.

          -  Patient must not have a CT and/or MRI with evidence of a non-ischemic mechanism,
             subarachnoid hemorrhage, or primary intracerebral and/or intraventricular hemorrhage.

          -  Patient must not have all three of the following findings:

               1. reduced level of consciousness (has score of greater than or equal to two on
                  NIHSS Question 1a)

               2. forced eye deviation or total gaze paresis (has score of 2 on NIHSS Question 2)
                  and

               3. dense hemiplegia (no movement) of upper and lower extremities (i.e., has score of
                  4 on NIHSS Question 5 regarding motor arm and has score of 4 on NIHSS Question 6
                  regarding motor leg).

          -  Patient must not have neurological signs and symptoms that are rapidly improving.

          -  Patient must not have a severe coexisting or terminal systemic disease.

          -  Patient must not be pregnant or lactating.

          -  Patient must not have impaired hepatic function; bilirubin greater than 2 mg/dL and or
             ascites.

          -  Patient must not have impaired renal function; serum creatinine greater than 2 mg/dL.

          -  Patient must not have congestive heart failure.

          -  Patient must not have a baseline ECG showing a PR interval greater than 200
             milliseconds, or a corrected QT interval of greater than 480 milliseconds, or a
             history of ventricular arrhythmias, or a Mobitz Type 1 or greater AV block.

          -  Patient must not have other exclusion criteria as specified in the study protocol.
Clinical trial NCT00238511 (phase 2, status: completed)
Conditions: postherpetic neuralgia
ICD codes: B02.22
Drugs: spm 927
SMILES: COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Postherpetic Neuralgia

        Exclusion Criteria:

          -  Does not benefit from long term treatment
Clinical trial NCT00634582 (phase 2, status: terminated)
Conditions: metastatic cancer, prostate cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: paricalcitol
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion:

          -  Histologically or cytologically confirmed advanced adenocarcinoma of the prostate

             - Radiographically proven bone metastasis from prostate cancer

          -  Androgen refractory disease (including anti-androgen withdrawal)

          -  Secondary hyperparathyroidism, defined as two parathyroid hormone (PTH) values > 70
             pg/mL, 14 days apart

          -  ECOG performance status 0-2

          -  Leukocytes ≥ 3,000/μL

          -  Absolute neutrophil count ≥ 1,500/μL

          -  Platelets ≥ 100,000/μL

          -  Total bilirubin normal

          -  AST/ALT ≤ 2.5 times upper limit of normal

          -  Creatinine clearance ≥ 60 mL/min

          -  Calcium normal

          -  25-hydroxyvitamin D (25-OHD) ≥ 20 ng/mL

          -  1,25(OH)_2D normal

          -  Patients with serum 25-OHD indicative of vitamin D insufficiency are eligible provided
             they are treated with ergocalciferol to raise 25-OHD levels to 20 ng/mL prior to
             paricalcitol therapy

          -  More than 8 weeks since prior bisphosphonates

          -  More than 2 weeks since prior palliative radiotherapy

          -  More than 4 weeks since other prior therapy

          -  No more than one prior taxane-containing chemotherapy regimen for metastatic disease

          -  Multiple lines of prior therapy with hormonal agents allowed

          -  Concurrent corticosteroids allowed provided the dose remains stable during the study
             period

        Exclusion:

          -  Underlying metabolic bone disease or vitamin D deficiency

          -  History of hypercalcemia

          -  Concurrent uncontrolled illness or co-morbid condition (including psychiatric illness)
             that would interfere with study compliance

          -  Concurrent ergocalciferol supplementation

          -  Concurrent chemotherapy or hormonal therapy

          -  Concurrent investigational or commercial agents for the malignancy
Clinical trial NCT00264147 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: etoricoxib, etoricoxib, etoricoxib, etoricoxib, comparator: placebo, etoricoxib, comparator: diclofenac
SMILES: CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O, CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O, CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O, CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O, CN(C)C(=N)NC(N)=N, CC1=NC=C(C=C1)C1=C(C=C(Cl)C=N1)C1=CC=C(C=C1)S(C)(=O)=O, OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with diagnosed rheumatoid arthritis (RA) for at least 6 months prior who is
             otherwise judged to be in general good health and who is currently taking nonsteroidal
             anti-inflammatory drugs (NSAIDS) to treat his/her RA symptoms

          -  Patient will need to stop taking these medications in order to participate, but can
             continue taking his/her other anti-rheumatic medications as long as they have been
             stable for certain periods of time

        Exclusion Criteria:

          -  Patients with a disease or medical condition(s) that could worsen or interfere with
             the evaluation of the effectiveness of study medication are not allowed to participate
Clinical trial NCT01021852 (phase 2, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: mk-6096, dose-matched placebo to mk-6096
SMILES: C[C@@H]1CC[C@@H](COC2=CC=C(F)C=N2)CN1C(=O)C1=CC(C)=CC=C1C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant is willing to stay overnight at a sleep laboratory on 6 separate nights
             and is willing to stay in bed for at least 8 hours each night while at the sleep
             laboratory

          -  Participant's regular bedtime is between 9 PM and 12 AM (midnight)

          -  Participant is able to read and complete questionnaires and diaries

          -  Participant is willing to refrain from napping during the study

        Exclusion Criteria:

          -  If female, participant is breast feeding, pregnant, or planning to become pregnant

          -  Participant is expecting to donate eggs or sperm during the study

          -  Participant has any history of a neurological disorder

          -  Participant has a history within the past 6 months of a cardiovascular disorder such
             as unstable angina, congestive heart failure or acute coronary syndrome.

          -  Participant has difficulty sleeping due to a medical condition

          -  Participant has donated blood products within the 8 weeks prior to the study

          -  Participant plans to travel across 3 or more time zones during the study

          -  Participant is currently participating or has participated in a study with an
             investigational compound or device within the last 30 days
Clinical trial NCT00084864 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: dexamethasone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Reason stopped: 
    sample size is too small to draw a conclusion
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Organ-confined disease

               -  cT1, cT2, or cT3 tumors

                    -  Patients with cT1 tumors are eligible if ≥ 1 core biopsies have ≥ 50% of the
                       tumor OR if 50% of the cores examined contain the tumor

               -  No small cell carcinoma of the prostate

          -  Scheduled for radical prostatectomy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Not specified

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Platelet count ≥ 100,000/mm^3

          -  WBC ≥ 3,500/mm^3

        Hepatic

          -  ALT and AST ≤ 4 times normal

          -  Bilirubin ≤ 2 mg/dL

        Renal

          -  Creatinine ≤ 2 times upper limit of normal

          -  Calcium ≤ 10.5 mg/dL

          -  No detectable renal stones by CT scan or ultrasound

        Other

          -  No history of diabetes mellitus requiring pharmacotherapy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  More than 5 years since prior antiestrogens, antiandrogens, luteinizing
             hormone-releasing hormone agonists, estrogen, or progestational agents

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

          -  No prior nephrectomy

          -  No prior prostatic surgery

          -  No prior cryotherapy or transurethral resection of the prostate
Clinical trial NCT00388960 (phase 2, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: amrubicin, cisplatin, etoposide
SMILES: [H][C@@]1(C[C@@](N)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=O)O[C@H]1C[C@H](O)[C@H](O)CO1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically/cytologically proven small cell lung cancer

          -  Extensive disease

          -  Measurable disease

          -  World Health Organization (WHO) performance status 0-2

          -  Age 18 years or older

          -  Normal baseline cardiac function

          -  No prior systemic chemotherapy for small cell lung cancer

          -  Adequate organ function including bone marrow, kidney, and liver

          -  No history of interstitial lung disease or pulmonary fibrosis

          -  No history of prior malignancy unless patient has been disease free for greater than 5
             years, or the tumour was a non-melanoma skin cancer or in-situ carcinoma of the cervix

          -  No pregnancy or breast feeding; patients of child-bearing potential must agree to use
             an appropriate method of contraception

          -  Written informed consent before randomization

        Exclusion criteria:

          -  Pre-existing peripheral neuropathy (greater than Grade 1, CTCAE version 3.0)

          -  Uncontrolled or severe cardiovascular disease

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule